Published in Bone on January 01, 1992
The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int (1993) 2.66
The hospital cost of vertebral fractures in the EU: estimates using national datasets. Osteoporos Int (2003) 1.38
Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ (1996) 1.38
Identification of vertebral fractures: an update. Osteoporos Int (2005) 1.34
Validation of the Dutch guidelines for dual X-ray absorptiometry measurement. Br J Gen Pract (2009) 1.16
Ethnic difference of clinical vertebral fracture risk. Osteoporos Int (2011) 1.08
Back pain remains a common symptom in old age. a population-based study of 4486 Danish twins aged 70-102. Eur Spine J (2003) 1.06
The hospital burden of vertebral fracture in Europe: a study of national register sources. Osteoporos Int (1997) 1.06
Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab (2008) 1.02
When, where and how osteoporosis-associated fractures occur: an analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS One (2013) 0.97
Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int (2012) 0.88
The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures. J Bone Miner Metab (2008) 0.85
Influence of maternal genetic and lifestyle factors on bone mineral density in adolescent daughters: a cohort study in 387 Japanese daughter-mother pairs. J Bone Miner Metab (2009) 0.80
Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study. J Bone Miner Metab (2009) 0.80
The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteoporosis (A-TOP) Research Group. J Bone Miner Metab (2006) 0.76
Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor‑κB ligand in osteoblasts in vivo and in vitro. Mol Med Rep (2015) 0.75
Effect of the Degenerative State of the Intervertebral Disk on the Impact Characteristics of Human Spine Segments. Front Bioeng Biotechnol (2013) 0.75
[Osteoporosis in 1993. An information update]. Can Fam Physician (1994) 0.75
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int (2001) 3.23
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int (2000) 2.99
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
Risk of vertebral fracture in women with rheumatoid arthritis. BMJ (1993) 1.87
A high incidence of vertebral fracture in women with breast cancer. Br J Cancer (1999) 1.74
Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos (2013) 1.72
The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol (1999) 1.60
Use of diphosphonates in hypercalcaemia due to malignancy. Lancet (1990) 1.47
Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis (1994) 1.46
Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol (1992) 1.39
Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone (1996) 1.38
Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: the Chingford Study. J Bone Miner Res (1993) 1.38
Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int (2000) 1.35
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res (1997) 1.35
Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas (2013) 1.34
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol (1998) 1.30
The effects of a FRAX revision for the USA. Osteoporos Int (2009) 1.12
Use of clinical risk factors to identify postmenopausal women with vertebral fractures. Osteoporos Int (2006) 1.11
Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess (2007) 1.09
A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®). Osteoporos Int (2011) 1.02
Treatment of skeletal disease in breast cancer with clodronate. Bone (1991) 1.01
Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int (2011) 1.00
Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int (2001) 1.00
Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med (1987) 0.98
A precise method for the assessment of tibial ultrasound velocity. Osteoporos Int (1996) 0.97
Lumbar spine texture enhances 10-year fracture probability assessment. Osteoporos Int (2014) 0.95
Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican Institute of Social Security. Osteoporos Int (2010) 0.94
SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos (2013) 0.94
A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int (2010) 0.94
Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer (1993) 0.92
Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res (1990) 0.92
Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study. Osteoporos Int (2013) 0.91
Worldwide uptake of FRAX. Arch Osteoporos (2014) 0.91
Evaluation of FRAX to characterise fracture risk in Poland. Osteoporos Int (2010) 0.90
How to decide who to treat. Best Pract Res Clin Rheumatol (2009) 0.90
Risk factors in osteoporosis. Maturitas (1998) 0.88
Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos (2015) 0.88
Tumour induced hypercalcaemia: a case for active treatment. Clin Oncol (R Coll Radiol) (1994) 0.87
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int (2009) 0.86
[A FRAX model for the assessment of fracture probability in Belgium]. Rev Med Liege (2009) 0.86
The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int (2007) 0.86
A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int (2013) 0.86
Rationale for the use of bisphosphonates in bone metastases. Bone (1991) 0.86
Studies of bone density, quantitative ultrasound, and vertebral fractures in relation to collagen type I alpha 1 alleles in elderly women. Calcif Tissue Int (2001) 0.86
Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int (2015) 0.85
Bone turnover and biochemical markers in malignancy. Cancer (1997) 0.85
Paget's disease of bone and unvaccinated dogs. Bone (1996) 0.85
Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos Int (2006) 0.85
Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporos Int (2013) 0.85
Development of a questionnaire (OPQ) to assess patient's knowledge about osteoporosis. Maturitas (2000) 0.84
Treatment of the hypercalcaemia of malignancy with intravenous clodronate. Bone (1987) 0.84
Bisphosphonates in multiple myeloma. Cancer (2000) 0.83
Evaluation of the risk of hip fracture. Bone (1996) 0.83
Estrogens, the menopause, and osteoporosis. Bone (1996) 0.83
Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporos Int (2009) 0.81
Effect of calcitonin on vertebral and other fractures. QJM (1999) 0.81
Osteoporotic fractures: an unusual presentation of haemochromatosis. Bone (1992) 0.81
Rationale for the use of clodronate in osteoporosis. Osteoporos Int (1993) 0.80
Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporos Int (2015) 0.79
Metacarpal morphometry using a semi-automated technique in the assessment of osteoporosis and vertebral fracture risk. Osteoporos Int (2000) 0.79
Calcium metabolism and myeloma and the treatment of hypercalcemia. Hematol Oncol (1988) 0.79
Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res (1996) 0.79
Ultrasound velocity and dual-energy X-ray absorptiometry in normal and pagetic bone. Bone (2000) 0.78
Intra-individual variation in fasting urinary calcium- and hydroxyproline-creatinine ratios measured in metabolic bone clinic patients as both outpatients and inpatients. Ann Clin Biochem (1994) 0.78
Short-term reproducibility of proximal femur bone mineral density in the elderly. Calcif Tissue Int (1998) 0.78
Stanozolol stimulates remodelling of trabecular bone and net formation of bone at the endocortical surface. Clin Sci (Lond) (1991) 0.77
The effect of alendronate on renal tubular reabsorption of phosphate. Bone Miner (1994) 0.77
Performance of clinical referral criteria for bone densitometry in patients under 65 years of age assessed by spine bone mineral density. Postgrad Med J (2003) 0.77
Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol (1999) 0.77
Oral clodronate as treatment of osteogenesis imperfecta. Arch Dis Child (2003) 0.77
The use of calcium in the management of osteoporosis. Bone (1999) 0.77
Duration of response with oral clodronate in Paget's disease of bone. Bone (1996) 0.76
Assessment of optimum duration of therapy with oral dichloromethylene diphosphonate (clodronate) in the treatment of Paget's disease. Semin Arthritis Rheum (1994) 0.76
The effects of intravenous alendronate in Paget's disease of bone. J Bone Miner Res (1995) 0.76
Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). Br J Cancer (1994) 0.76
Transient taste-loss during treatment with etidronate. Lancet (1987) 0.76
Contribution of calcium and other dietary components to global variations in bone mineral density in young adults. Food Nutr Bull (2002) 0.76
A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clin Sci (Lond) (1990) 0.76
Is a calculated total hip BMD of clinical use? Osteoporos Int (2000) 0.75
Clodronate. Cancer (1997) 0.75
Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone (1995) 0.75
Treatment of osteoporosis with vitamin D. Osteoporos Int (1997) 0.75
Treating Paget's disease. Br Med J (Clin Res Ed) (1987) 0.75
An age- and sex-controlled matched pair analysis of T scores in ethnic Indians with hip fractures. J Orthop Surg (Hong Kong) (2004) 0.75
Alendronate in the treatment of Paget's disease of bone. Bone (1997) 0.75
Events per person year. A decrease in multiple events may be missed. BMJ (1995) 0.75
Discussion: Newer bisphosphonates in the treatment of Paget's disease of bone: where we are and where we want to go. J Bone Miner Res (1999) 0.75